Clinical trial
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
Recruiting now · Not applicable · 1 countries · Registry ID NCT04232566
Recruiting nowNot applicableObservational
What this study is about
This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin resistance.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age30 Years to 70 Years
SexAll
Healthy volunteersAccepted
ConditionObesity, Morbid, NASH - Nonalcoholic Steatohepatitis, Chronic Inflammation
Full registry criteria
Inclusion Criteria: * Undergoing gastric bypass surgery * Confirmed AUROC F=0 or F\>2 liver fibrosis * Age 30-70 years * BMI greater than 40 kg/m2 * Negative pregnancy test (female only) * Lab Values: Normal TSH Exclusion Criteria: * Autoimmune diseases * Hepatitis B or C positive * Heavy alcohol use * Active smoking history * Active cancer history * History of asthma * History of COPD * Taking Plavix or Coumadin * Blood donation within past 2 months * Glucocorticoid Therapy * Taking antihistamine on regular basis
Treatments and study arms
Bariatric surgery
Procedure
Evaluate liver fibrosis by elastography before gastric bypass surgery.
Primary outcomes
Liver fibrosisBaseline
evaluate the liver fibrosis by elastography before surgical intervention
Adipose tissue inflammationBaseline
Evaluate markers of adipose tissue inflammation by mRNA levels
Study locations
1 locations were listed when this page was built. The first 40 are shown.
Mayo Clinic in Arizona🇺🇸 Scottsdale, Arizona, United States
Stewart KeeganContact
Elena De Filippis, MD,PhDPrincipal Investigator